Our findings reveal that CHRNA5 RNAi could act as a candidate CHEK1 inhibitor leading to enhanced drug sensitivity in breast cancer cells and warrants further studies in different cell lines and cancers. This evidence concerns the gene CHRNA5 and breast carcinoma.